DOI: https://doi.org/10.14710/jai.v0i0.62676

Malignant Hyperthermia

Department of Anesthesiology and Intensive Therapy , RSUD Arifin Achmad, Riau University, Jl Diponegoro, Pekanbaru, Riau, Indonesia 28133, Indonesia

Received: 17 Mar 2024; Revised: 22 May 2025; Accepted: 4 Jun 2025; Available online: 10 Jun 2025.
Open Access Copyright 2021 JAI (Jurnal Anestesiologi Indonesia)
Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 International License.

Citation Format:
Cover Image
Abstract
Malignant hyperthermia (MH) is a life-threatening clinical syndrome caused by hypermetabolism involving skeletal muscle. MH is very rare, but is one of the causes of death in the operating room. MH is an autosomal dominant disease and can be triggered when exposed to certain anesthetic drugs. There are genetic tests that can help make a diagnosis, but the gold standard is the caffeine halothane contracture test (CHCT). Initial symptoms are decrease in pH and oxygen, as well as an increase in CO2, lactate, potassium, and temperature. The increase in lactate is reflecting tissue hypoxia. Dantrolene is an antidote to MH, by reducing calcium loss from the sarcoplasmic reticulum in skeletal muscle and returning metabolism to normal conditions. Immediate detection and treatment can improve MH outcomes

Note: This article has supplementary file(s).

Fulltext View|Download |  common.other
Copyright Transfer Agreement
Subject
Type Other
  Download (60KB)    Indexing metadata
Keywords: anesthesia; autosomal dominant; dantrolene; hypermetabolism; malignant hyperthermia

Article Metrics:

Article Info
Section: Literature Reviews
Language : ID
Recent articles
Thoracic Spinal Anesthesia (TSA) in Patients with Congestive Heart Failure and Pleural Effusion Undergoing Breast Tumor Surgery: A Case Report NUTRITION THERAPY IN POST-HARTMANN PROCEDURE PATIENTS IN THE INTENSIVE CARE UNIT Rare Case of Neurosurgical Anesthesia in a Patient with Recidive Cystic Tumor and Cerebral Edema Re-craniotomy tumor excision and decompression: Case Report Combination of Vitamin D and Vitamin E Against Bacterial Infections Malignant Hyperthermia More recent articles
Most cited articles
Midazolam Intravena Dosis Rendah Tidak Mempengaruhi Nitric Oxide Intraperitoneal Mencit Balb/C Yang Terpapar Lipopolisakarida Patofisiologi Penyakit Jantung Koroner More cited articles
  1. Gravenstein N, Kirby RR. Malignant Hyperthermia. In Gravenstein N, Kirby RR (ed), Complications in Anesthesiology. 2nd ed. Philadelphia 1996. Lippincott Raven: 141-158
  2. Larach MG, Gronert GA, Allen GC, Brandon BW, Lehman EB: Clinical presentation, treatment and complications of malignant hyperthermia in North American from 1987 to 2006. Anesth Analg 2010, 110: 498-507
  3. Soenarto RF. Hipertermia Maligna. In Soenarto RF, Chandra S. Buku Ajar Anestesiologi. Dept Anestesiologi dan Intensive Care FK UI/RSCM. 2012: 275-87
  4. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet Journal of Rare Diseases. 2007 Apr 24;2(1)
  5. Schuster F, Roewer N, Schneiderbanger D, Johannsen S. Management of malignant hyperthermia: diagnosis and treatment. Therapeutics and Clinical Risk Management. 2014 May;10:355
  6. Rosenberg H, Sambuughin NK, Dirksen R: Malignant hyperthermia susceptibility in GeneReviews Edited by Pagon RA, Bird TD, Dolan CR Stephens K. Seattle (WA): University of Washington; 2011
  7. Chaube R, Hess DT, Wang YJ, Plummer B, Sun QA, Laurita K, et al. Regulation of the skeletal muscle ryanodine receptor/Ca2+-release channel RyR1 by S-palmitoylation. J Biol Chem. 2014;289(12):8612–9
  8. Gronert GA, Antogini JF. Malignant Hyperthermia. In Miller RD (ed), Anesthesia 8th ed. Philadelphia 2015. Churchill Livingstone: 1033-1050
  9. Mescher AL. Muscle tissue. Junqueira’s Basic Histology Text & Atlas (Twelfth Edition). New York: Mc GrawHill, 2010
  10. Morgan GE, Mikhail MS. Thermoregulation, Hypothermia, & Malignant Hyperthermia. In Morgan GE (ed), Clinical Anesthesiology 5th ed. McGraw-Hill.2013: 1183-92
  11. Khalar R. Making Malignant Hyperthermia Cool. St. David Medical Center, Austin, Texas. 2014
  12. Lin HT, Wang SC, Zuo Z, Tsou MY, Chan KH, Yuan HB. Increased requirement for minute ventilation and negative arterial to end-tidal carbon dioxide gradient may indicate malignant hyperthermia. Journal of the Chinese Medical Association. 2014 Apr 1 ;77(4):209–12
  13. Burkman James M, Posner Karen L, Domino Karen B. Analysis of the Clinical Variables Associated with Recrudescence after Malignant Hyperthermia Reactions. Anesthesiology. 2007 May 1;106(5):901–6
  14. Ward A, Chaffman MO, Sorkin EM. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986;32: 130–68
  15. Fruen BR, Mickelson JR, Louis CF. Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors.Journal of Biological Chemistry1997;272: 26965–71
  16. Tortora GJ, Derrickson B. Muscular tissue. Principles of Anatomy & Physiology (Thirteenth Edition). Danvers: John Wiley & Sons Inc, 2012

Last update:

No citation recorded.

Last update: 2025-06-17 17:43:43

No citation recorded.